Shelly Pinto compensation by year
ALX ONCOLOGY Summary Compensation Table · all 2 fiscal years held| Component | FY2021 | FY2024 |
|---|---|---|
| Salary | $226,667 | $378,776 |
| Bonus | $75,000 | $25,000 |
| Stock awards | $0 | $396,000 |
| Option awards | $6,724,110 | $582,965 |
| Non-equity incentive | $90,542 | $122,420 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $0 |
| Total | $7,116,319 | $1,505,161 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ALX ONCOLOGY HOLDINGS INC DEF 14A filed April 21, 2025, accession 0000950170-25-056291, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ALX ONCOLOGY HOLDINGS INC filed document, accession 0000950170-25-056291. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 18,750 | $31,313 | — |
| RSU | 16,250 | $27,138 | — |
| PSU | 13,125 | $21,919 | — |
| RSU | 10,000 | $16,700 | — |
| RSU | 4,125 | $6,889 | — |
| Option | 3,646 | — | $58.56 |
| Option | 13,021 | — | $62.83 |
| Option | 150,000 | — | $1.66 |
| Option | 27,709 | — | $15.84 |
| Option | 14,250 | — | $11.47 |
| Option | 23,250 | — | $5.86 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ALX ONCOLOGY HOLDINGS INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
10 Form 4 lines since the FY2024 proxy (filed April 21, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-17 | Sale | — | 573 | $1.93 | 87,828 |
| 2026-07-01 | Sale | — | 1,404 | $2.04 | 88,401 |
| 2026-03-19 | Sale | — | 903 | $2.17 | 86,805 |
| 2026-02-18 | Sale | — | 565 | $2.27 | 87,708 |
| 2026-01-26 | Grant or award derivative | — | 192,000 | $0.00 | 192,000 |
| 2026-01-06 | Sale | — | 3,925 | $1.11 | 88,273 |
| 2025-10-14 | Grant or award derivative | — | 140,000 | $0.00 | 140,000 |
| 2025-08-15 | Sale | — | 611 | $0.64 | 89,198 |
The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
ALX ONCOLOGY’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Jason Lettmann | Chief Executive Officer | $6,640,830 |
| Sophia Randolph | Former Chief Medical Officer | $3,530,138 |
| Jaume Pons | Former President and Chief Scientific Officer | $3,017,955 |
| Peter Garcia | Former Chief Financial Officer | $2,697,079 |
| Shelly Pinto · this page | Senior Vice President, Finance and Chief Accounting Officer | $1,505,161 |
| Shelly Wong | Senior Vice President, Finance and Chief Accounting Officer | $1,505,161 |
The full ALX ONCOLOGY compensation record
free company briefThis page is one person within ALX ONCOLOGY's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ALX ONCOLOGY proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ALX ONCOLOGY's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.